HIV-Associated Lipodystrophy Treatment Market Size is valued at USD 176.82 Mn in 2023 and is predicted to reach USD 239.62 Mn by the year 2031 at a 4.05% CAGR during the forecast period for 2024-2031.
HIV-associated lipodystrophy is an unfavourable side effect of antiretroviral therapy (ART). Lipodystrophy, often HIV-associated lipodystrophy, is a disease unique to HIV-positive people. Facial, gluteal, thigh, and limb subcutaneous fat all diminish. HIV-infected persons taking antiretroviral medicines have been linked to an increased risk of developing HIV-associated lipodystrophy, albeit these findings have not been replicated across the board. The face, thighs, upper arms, and lower legs are vulnerable to lipoatrophy.
Truncal lipohypertrophy, on the other hand, can cause various symptoms, including belly fat, breast enlargement, a floppy neck, and even lipomas. Facial lipoatrophy, in particular, has been related to low mood, low self-esteem, sexual dysfunction, and social isolation, which can devastatingly affect a patient's well-being and mobility and adhere to antiretroviral therapy (ART). Furthermore, the increased risk of cardiovascular disease is just one way lipodystrophy contributes to morbidity. Other ways include the development of insulin resistance, hyperlipidemia, and endothelial dysfunction. This highlights the critical nature of early diagnosis and treatment for HIV-related lipodystrophy.
However, the market growth is hampered by the lack of knowledge of the safety and health of the HIV-associated lipodystrophy treatment market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high humidity HIV-associated lipodystrophy treatment, a lack of a solid foundation for the control programs; problems with drug availability; a lack of patient commitment to treatment; the presence of co-morbidities and opportunistic infections.
Patients may stop taking their HIV medication because they are afraid of developing lipodystrophy or because they worry that having lipodystrophy will make their HIV status clear to doctors. COVID-19 vaccinations are safe for use in HIV patients. Clinical studies of the COVID-19 vaccine were conducted on people living with HIV. The vaccinations against COVID-19 are safe, productive, and of high enough quality to be approved by the FDA. Diseases are monitored and prevented by the (CDC) reports. There is no evidence that the COVID-19 vaccination is incompatible with HIV treatment or prevention drugs.
The HIV-Associated Lipodystrophy Treatment Market is segmented based on lipodystrophy type, therapeutic class, and distribution channel. Based on lipodystrophy type, the market is segmented into lipoatrophy and lipoaccumulation. By therapeutic class, the market is segmented into anabolism modulators, Growth hormones, anabolic steroids, insulin resistance modulators, metformin, thiazolidinediones, mitochondrial antioxidants (l-carnitine), and other miscellaneous metabolic agents. The distribution channel segment is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The growth hormones HIV-associated lipodystrophy treatment is expected to lead with a significant global market share in 2024. Growth hormone's functions include affecting height and assisting in bone and muscular development. Growth hormone levels vary naturally throughout the day, seemingly in response to levels of physical exertion.
The online pharmacy administration system is designed to remove physical constraints. It paves the way for telehealth services, allowing pharmacists to assist patients physically distant from them, facilitate remote order processing, and introduce new avenues for patient connection, especially in countries like the US, Germany, the UK, China, and India.
The North American HIV-associated lipodystrophy treatment market is expected to record the maximum market share in revenue in the near future. It can be attributed to the good terms of the insurance coverage. Insurance coverage for the treatment of HIV drug side effects such as HIV-related lipodystrophy was recently granted by both the Massachusetts House and Senate. The market for treatments for HIV-related lipodystrophy is anticipated to flourish due to the acceptance of such insurance coverage. In addition, Asia Pacific is estimated to grow rapidly in the global HIV-associated lipodystrophy treatment market because of a confluence of factors that emphasize the importance of a shift in perspective, improved access to care, and a heightened sense of patient agency. An ageing population and a growth in the prevalence of chronic diseases have raised the profile of advanced care planning in the region.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 176.82 Mn |
|
Revenue Forecast In 2031 |
USD 239.62 Mn |
|
Growth Rate CAGR |
CAGR of 4.05% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
by Lipodystrophy Type, by Therapeutic class, by Distribution Channels |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Theratechnologies Inc., GlaxoSmithKline plc, Novelion Therapeutics Inc., AstraZeneca plc, AbbVie Inc., and Bristol-Myers Squibb, Amryt Pharmaceuticals, Inc., Fawn Incorporation, Abbott Healthcare Solutions, Lupin Pharmaceuticals, Inc., Pfizer Inc., Bayer Inc., Novartis Pharmaceuticals Corporation, Galderma Laboratories, L.P., and Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global HIV-associated lipodystrophy treatment Market Snapshot
Chapter 4. Global HIV-associated lipodystrophy treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Lipodystrophy type Estimates & Trend Analysis
5.1. By Lipodystrophy type, & Market Share, 2019 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Lipodystrophy type:
5.2.1. Lipoatrophy
5.2.2. Lipoaccumulation
Chapter 6. Market Segmentation 2: By Therapeutic class Estimates & Trend Analysis
6.1. By Therapeutic class & Market Share, 2019 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Therapeutic class:
6.2.1. Anabolism modulators
6.2.2. Growth hormones
6.2.3. Anabolic steroids
6.2.4. Insulin resistance modulators
6.2.5. Metformins
6.2.6. Thiazolidinediones
6.2.7. Others
6.2.8. Mitochondrial antioxidants (l-carnitine)
6.2.9. Other miscellaneous metabolic agents
Chapter 7. Market Segmentation 3: By Distribution channel Estimates & Trend Analysis
7.1. By Distribution channel & Market Share, 2019 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Distribution channel:
7.2.1. Hospital pharmacies
7.2.2. Retail pharmacies
7.2.3. Online pharmacies
Chapter 8. HIV-associated lipodystrophy treatment Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America HIV-associated lipodystrophy treatment Market revenue (US$ Million) estimates and forecasts By Lipodystrophy type, 2024-2031
8.1.2. North America HIV-associated lipodystrophy treatment Market revenue (US$ Million) estimates and forecasts By Therapeutic class, 2024-2031
8.1.3. North America HIV-associated lipodystrophy treatment Market revenue (US$ Million) estimates and forecasts By Distribution channel, 2024-2031
8.1.4. North America HIV-associated lipodystrophy treatment Market revenue (US$ Million) estimates and forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Lipodystrophy type, 2024-2031
8.2.2. Europe HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Therapeutic class, 2024-2031
8.2.3. Europe HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Distribution channel, 2024-2031
8.2.4. Europe HIV-associated lipodystrophy treatment Market revenue (US$ Million) by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Lipodystrophy type, 2024-2031
8.3.2. Asia Pacific HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Therapeutic class, 2024-2031
8.3.3. Asia Pacific HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Distribution channel, 2024-2031
8.3.4. Asia Pacific HIV-associated lipodystrophy treatment Market revenue (US$ Million) by country, 2024-2031
8.4. Latin America
8.4.1. Latin America HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Lipodystrophy type, (US$ Million) 2024-2031
8.4.2. Latin America HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Therapeutic class, (US$ Million) 2024-2031
8.4.3. Latin America HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Distribution channel, (US$ Million) 2024-2031
8.4.4. Latin America HIV-associated lipodystrophy treatment Market revenue (US$ Million) by country, 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Lipodystrophy type, (US$ Million) 2024-2031
8.5.2. Middle East & Africa HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Therapeutic class, (US$ Million) 2024-2031
8.5.3. Middle East & Africa HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Distribution channel, (US$ Million) 2024-2031
8.5.4. Middle East & Africa HIV-associated lipodystrophy treatment Market revenue (US$ Million) by country, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Theratechnologies Inc.,
9.2.2. GlaxoSmithKline plc,
9.2.3. Novelion Therapeutics Inc.,
9.2.4. AstraZeneca plc, AbbVie Inc.,
9.2.5. Bristol-Myers Squibb.
HIV-Associated Lipodystrophy Treatment Market By lipodystrophy type:
HIV-Associated Lipodystrophy Treatment Market By therapeutic class-
HIV-Associated Lipodystrophy Treatment Market By distribution channel-
HIV-Associated Lipodystrophy Treatment Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
